Vol. 19/No. 13 | OncologyLive

MDM2 Inhibitor May Improve Response in AML

July 09, 2018

Investigators are hopeful that idasanutlin, a novel small molecule that targets the MDM2 protein, can improve the efficacy of chemotherapy in patients with relapsed/refractory acute myeloid leukemia.

Marshall Makes the Case for Molecular Sorting in Gastrointestinal Disease

July 03, 2018

Oncologists have been slow to introduce targeted and immune therapies into the treatment of gastrointestinal cancers, but that is changing, and poor patient survival statistics call for a continuation of this trend, according to John L. Marshall, MD.

Researchers Focus on Putting the STING Back Into Immune Response

July 03, 2018

Recently, immuno-oncologists have turned their attention to the role of the second arm of the immune response—the more rough-and-ready innate arm, which serves as the body’s frontline defense against pathogenic invaders and, it seems, cancer.

Choose the Right Organizational Model for Oncology Practice Success

July 01, 2018

Many pressures on independent oncology practices have contributed to regionalization of services, in which practices merge or establish relationships with larger health systems. The forms that these larger systems have taken are diverse, but they do fall into several basic categories.

Team Spirit Guides Gandara in Personalizing Care

June 30, 2018

David R. Gandara, MD, has pioneered groundbreaking therapies in lung cancer treatment through his leadership of interdisciplinary teams of oncologists, pharmacologists, molecular biologists, and statisticians.

ACR and SBI Recommend Universal Breast Cancer Risk Assessment at Age 30

June 29, 2018

New breast cancer screening guidelines from the American College of Radiology and Society of Breast Imaging advise all women to undergo risk assessment at age 30, followed by screening for those with a greater chance of cancer.

The Comorbidity Checklist: New Strategies Needed for Cancer Care

June 28, 2018

Patients with cancer have high rates of comorbidities, but hard data are often lacking about the interaction of specific regimens with such health conditions. Experts say more inclusive clinical trials and broader use of risk assessment tools would help improve care.

Ovarian Cancer Incidence, Mortality Decline But Access to Care Is Not Equal

June 26, 2018

Ovarian cancer incidence and mortality have declined significantly over the past few decades, but eliminating racial disparities in treatment and improving prevention and early detection could help save even more women.

Findings Set Stage for Expanded Immunotherapy Role in Bladder Cancer

June 26, 2018

Researchers now are turning their attention toward earlier disease settings involving patients who are refractory to standard therapies in nonmuscle-invasive bladder cancer or who are poor candidates for surgery in muscle-invasive bladder cancer.